Gi Jung - DongKook Pharmaceutical Managing Director
| 086450 Stock | KRW 16,590 240.00 1.47% |
Managing Director
Jung Gi Ho is Managing Director of DongKook Pharmaceutical Co. Ltd. Previously Jung was a Member of the Company Board of Directors. Jung also worked for Bayer in Korea and SYNTEX KOREA CO. LTD. Jung received a Bachelor degree in Textile Engineering from Dankook University Korea in February 1984. since 2007.
| Age | 54 |
| Tenure | 17 years |
| Phone | (82) 2 566 8542 |
| Web | www.dkpharm.co.kr |
DongKook Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0608 % which means that it generated a profit of $0.0608 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 12.717 %, meaning that it generated $12.717 on every $100 dollars invested by stockholders. DongKook Pharmaceutical's management efficiency ratios could be used to measure how well DongKook Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 |
DongKook Pharmaceutical Leadership Team
Elected by the shareholders, the DongKook Pharmaceutical's board of directors comprises two types of representatives: DongKook Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DongKook. The board's role is to monitor DongKook Pharmaceutical's management team and ensure that shareholders' interests are well served. DongKook Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DongKook Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gyeong Cha, Managing Director | ||
| GyuJin Lee, Managing Management | ||
| Bong Cho, Assistant Managing Director | ||
| HongKi Kim, Director Fin | ||
| Heung Oh, Chief Executive Officer, Director | ||
| Gi Kwon, Vice Chairman of the Board | ||
| Jae Park, Assistant Managing Director | ||
| HeeSoon Park, Managing Marketing | ||
| Mok Park, Managing Director | ||
| Se Jeon, Assistant Managing Director | ||
| Gi Jung, Managing Director | ||
| YoungWook Lee, Pres CEO | ||
| BongHo Cho, Managing Sales | ||
| Byeong Yoo, Managing Director | ||
| Seung Pyo, Assistant Managing Director | ||
| Gyu Jung, Internal Auditor | ||
| Hui Kim, Managing Director | ||
| Tae Kim, Assistant Managing Director | ||
| HeungJu Oh, VP CEO | ||
| SoonKang Hong, Managing PR | ||
| SeIl Jeon, Managing Sales | ||
| JoonHo Song, Managing Planning | ||
| JeWon Park, Managing Sales | ||
| Byeong Yeo, Director |
DongKook Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DongKook Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 1.08 T | |||
| Shares Outstanding | 8.79 M | |||
| Shares Owned By Insiders | 46.60 % | |||
| Shares Owned By Institutions | 17.00 % | |||
| Price To Earning | 19.52 X | |||
| Price To Sales | 0.24 X |
Pair Trading with DongKook Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DongKook Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DongKook Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to DongKook Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DongKook Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DongKook Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DongKook Pharmaceutical Co to buy it.
The correlation of DongKook Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DongKook Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DongKook Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DongKook Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in DongKook Stock
DongKook Pharmaceutical financial ratios help investors to determine whether DongKook Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DongKook with respect to the benefits of owning DongKook Pharmaceutical security.